Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study

Objective: Pembrolizumab and bevacizumab both have antitumor activity. According to NCCN updated guideline the benefit of pembrolizumab or bevacizumab as a first line in management of advanced nonsmall cell lung cancer (NSCLC) is documented in randomized controlled studies. The study aimed to evalua...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jie, Wu, Di, Zhang, Ziran, Long, Jieran, Tian, Guangming, Wang, Yang, Ma, Xiangjuan, Chen, Xiaoling, Han, Jindi, Hu, Weiheng, Dai, Ling, Nie, Jun, Fang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649085/
https://www.ncbi.nlm.nih.gov/pubmed/34821175
http://dx.doi.org/10.1177/15330338211039676

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649085/
https://www.ncbi.nlm.nih.gov/pubmed/34821175
http://dx.doi.org/10.1177/15330338211039676

Ejemplares similares